BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ZContent.net//ZapCalLib 1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY:Development of Radiotheranostic Combo [64/67Cu]Cu-SAR-bisPSMA for P
 rostate Cancer: A Blueprint for Future Cu-based Radiotheranostic Agents
LOCATION:Chemistry A101
TZID:America/Denver
DTSTART:20251104T160000
UID:2026-05-21-05-54-27@natsci.colostate.edu
DTSTAMP:20260521T055427
Description:About the seminar:\n\n[64/67Cu]Cu-SAR-bisPSMA is a radiotherano
 stic agent which received a fast-track designation by the FDA earlier this
  year and is currently in clinical trials. Copper radioisotopes are underu
 tilized in radiopharmaceuticals due to thermodynamic and kinetic instabili
 ty of Cu2+ ions in vivo with many of the common chelators used in radio
 pharmaceuticals such as cyclam\, DOTA\, and TETA. Sarcophagine (SAR) is a 
 macrocyclic chelator that provides excellent stability with Cu2+ and allo
 ws for bivalent functionalization with targeting peptides for proteins suc
 h as Prostate-Specific Membrane Antigen (PSMA)\, which is overexpressed on
  prostate cancer tumors. [64/67Cu]Cu-SAR-bisPSMA is a significant develop
 ment in radiopharmaceuticals due to the stability of SAR with Cu2+ radioi
 sotopes\, 64Cu’s longer half-life than other radioisotopes used with PS
 MA agents\, bivalent functionalization of the chelator which enhances bind
 ing of the agent\, and the ability to design a theranostic combo for one t
 ype of ion. This seminar will examine the historical development of Sarcop
 hagine as a chelator and its application to Cu-based radiopharmaceuticals.
  4:00 pm
END:VEVENT
END:VCALENDAR